ArticleCancer immunology, immunotherapy : CII2023
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 3 citations in OpenAlex.
- Assessment of the Novel rVSV-PD-1-4-1BBL Oncolytic Activity on Mouse and Human Cancer Cell Lines.Biomedicines · 2026Article
- Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.Cellular and molecular life sciences : CMLS · 2026Article
- Unraveling the inflammatory bridge: genomic evidence identifies TNFRSF9 as a potential biomarker linking Sjögren's syndrome to total risk non-Hodgkin lymphoma.Clinical rheumatology · 2026Article
- Pediatric bronchiolitis disease severity is associated with immune checkpoint dysregulation.Pediatric research · 2026Article
- Integrative bioinformatics and machine learning approaches identify novel diagnostic signatures for oxaliplatin-resistant colorectal cancer.International journal of colorectal disease · 2026Article
- Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Research square · 2026Article
- Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment.Theranostics · 2026Article
- FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Targeting co-stimulatory receptors promotes the activation and effector functions of anti-tumor lymphocytes. 4-1BB (CD137/TNFSF9), a member of the tumor necrosis factor receptor superfamily (TNFR-SF), is a potent co-stimulatory receptor that plays a prominent role in augmenting effector functions of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.